<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003136</url>
  </required_header>
  <id_info>
    <org_study_id>8433</org_study_id>
    <secondary_id>UCCRC-8433</secondary_id>
    <secondary_id>ALZA-97-005-ii</secondary_id>
    <secondary_id>NCI-V97-1357</secondary_id>
    <nct_id>NCT00003136</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase I/II Dose Escalation Trial of Carboplatin With Amifostine Pretreatment to Augment High Dose Cyclophosphamide With Autologous Peripheral Blood Stem Cell Support for the Treatment of Patients With Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of amifostine, carboplatin and&#xD;
      cyclophosphamide, followed by peripheral stem cell transplantation, in treating patients with&#xD;
      epithelial ovarian cancer or primary peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose of high dose carboplatin with a fixed&#xD;
      dose of high dose cyclophosphamide with amifostine pretreatment, and peripheral blood stem&#xD;
      cell rescue in patients with ovarian epithelial cancer. II. Monitor engraftment kinetics such&#xD;
      as granulocyte and platelet recovery. III. Determine the toxic effects of this regimen in&#xD;
      this patient population. IV. Document the response of this patient population to this regimen&#xD;
      in terms of time to progression, event free survival, and overall survival.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study. Patients undergo apheresis over 2-4 days to&#xD;
      mobilize peripheral blood stem cells (PBSC). They then receive amifostine IV over 15 minutes.&#xD;
      Fifteen minutes later, carboplatin is administered over 30 minutes on days -6 through -3.&#xD;
      Cyclophosphamide IV is administered 1 hour after the carboplatin infusion is completed on&#xD;
      days -6 through -4. PBSC are infused on day 0. Filgrastim (G-CSF) is administered beginning&#xD;
      on day 4. Cohorts of 3-6 patients are treated at each dose level. At least 15 days must pass&#xD;
      between the day of PBSC infusion and the next dose escalation. The dose limiting toxicity&#xD;
      (DLT) is defined as the dose producing grade 3 or 4 nonhematologic toxicity in 2 of 6&#xD;
      patients. The maximum tolerated dose (MTD) is defined as one dose level below the DLT dose.&#xD;
      At least 6 patients are treated at the MTD. Patients are followed monthly for 6 months, every&#xD;
      2-3 months for 1 year, and annually until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: This study will accrue 28 patients over 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1996</start_date>
  <completion_date type="Actual">October 2001</completion_date>
  <primary_completion_date type="Actual">December 2000</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide (40mg/kg/day on days -6, -5 and -4), Carboplatin (1600, 1700 or 1800 mg/m2 on days -6, -5, -4 and -3), Amifostine (910 mg/m2 on days -6, -5, -4 and -3), Peripheral blood stem cell transplantation (day 0), G-CSF (beginning day 4)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amifostine trihydrate</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven ovarian epithelial cancer or primary&#xD;
        peritoneal carcinoma No tumors of low malignant potential Chemotherapy sensitive disease&#xD;
        Relapse greater than 6 months after complete response to chemotherapy Partial response to&#xD;
        most recent chemotherapy No more than 3 prior chemotherapy regimens Evidence of refractory&#xD;
        or recurrent disease other than elevated CA-125 after primary surgery or chemotherapy;&#xD;
        persistent disease need not be still present No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 65 and under Performance status: GOG 0 or 1 Life expectancy:&#xD;
        Not specified Hematopoietic: WBC greater than 2500/mm3 Platelet count greater than&#xD;
        100,000/mm3 Hepatic: Bilirubin normal Renal: Creatinine clearance at least 50 mL/min&#xD;
        Cardiovascular: Normal radionuclide cardiac scan with ejection fraction greater than 45% OR&#xD;
        Normal left ventricular function by echocardiogram OR Cardiac clearance by Cardiology&#xD;
        service Pulmonary: DLCO greater than 50% predicted Other: Not pregnant Hepatitis B and C&#xD;
        negative HIV-1 negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David L. Grinblatt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2004</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Amifostine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

